PharmaTher To Develop Digital Therapeutics Platform Focused On Psychedelic Therapies
Pharmather Inc (CSE: PHRM) this morning announced that it has amended its sponsored research agreement with that of the University
Read more
Pharmather
Artificial Intelligence Meets Psychedelics – The Daily Dive feat Fabio Chianelli
Today on the Daily Dive, Fabio Chianelli, CEO of PharmaTher Inc (CSE: PHRM) sits down with our host Cassandra Leah
Read more
Revive Therapeutics, Pharmather Partner On Psilocybin Cancer Research
Revive Therapeutics (CSE: RVV) and Pharmather Inc (CSE: PHRM) this morning jointly announced a research collaboration between the two firms.
Read more
Pharmather Appoints Dr Alberto J Espay As Scientific Advisor
Pharmather Inc (CSE: PHRM) has appointed a prolific Parkinson’s researcher to its team of scientific and clinical advisors. The company
Read more
Pharmather Files For Orphan Drug Status For Use Of Ketamine Against Postherpetic Neuralgia
Pharmather Inc (CSE: PHRM) this morning announced that it has filed for orphan drug status with the United States Food
Read more
Pharmather Enters Exclusive Arrangement For Psychedelic Delivery Tech
Pharmather Inc (CSE: PHRM) this morning announced that it has entered into an exclusive license agreement for the development and
Read more
Pharmather Applies For Orphan Drug Status For Ketamine In Use Against Parkinson’s Disease
Pharmather Inc (CSE: PHRM) has filed for orphan drug designation with the US Food and Drug Administration for the use
Read more
Pharmather Acquires Exclusive License For Ketamine Treatment Against Parkinson’s Disease
Pharmather Inc (CSE: PHRM) this morning announced that it has entered into an exclusive licensing agreement for the development and
Read more
Pharmather: Combining Artificial Intelligence With Psychedelics For Novel Drug Discovery
Newscope Capital, whom is currently doing business as Pharmather (CSE: PHRM) is the latest firm to begin trading on the
Read more